Search results for view 2

Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a read more »
Discuss   Add this link to...  Bury